Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 1/20 | 0.46 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.42 |
| ▸ | CDK2 | P24941 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | MAP3K5 | Q99683 | 1/20 | 0.37 |
| ▸ | CDK1 | P06493 | 3/20 | 0.36 |
| ▸ | CCNB1 | P14635 | 3/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 3/20 | 0.36 |
| ▸ | CCNA1 | P78396 | 3/20 | 0.36 |
| ▸ | MGMT | P16455 | 3/20 | 0.36 |
| ▸ | PI4KA | P42356 | 2/20 | 0.36 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.36 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.36 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | XDH | P47989 | 1/20 | 0.36 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2470033 | 0.85 | PNP (0.42) | PNPDPP4PDPK1GDACDK2 | |
| SCHEMBL41788 | 0.78 | PNP (0.50) | PNPDPP4PDPK1GDACDK2 | |
| SCHEMBL30542971 | 0.77 | XDH (0.41) | PNPDPP4GDAALDH1A1XDH | |
| SCHEMBL20579 | 0.77 | DPP4 (0.50) | PNPDPP4PDPK1GDACDK2 | |
| SCHEMBL8886040 | 0.77 | PNP (0.49) | PNPDPP4PDPK1GDACDK2 | |
| SCHEMBL1843777 | 0.77 | PNP (0.49) | PNPDPP4PDPK1GDACDK2 | |
| SCHEMBL27975255 | 0.77 | PNP (0.49) | PNPDPP4PDPK1GDACDK2 | |
| SCHEMBL2983851 | 0.77 | PNP (0.49) | PNPDPP4PDPK1GDACDK2 | |
| SCHEMBL20867 | 0.77 | ATAD2 (0.53) | PNPDPP4PDPK1GDALMNA | |
| SCHEMBL2051365 | 0.77 | PNP (0.49) | PNPDPP4PDPK1GDACDK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023146475-A2 | METHOD FOR DETERMINING GENOTOXICITY | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2023-08-03 | — | — | WO | disclosed |
| US-8597900-B2 | Compositions and methods for the treatment of cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-12-03 | — | — | US | disclosed |
| US-20130280258-A1 | PROGNOSTIC, DIAGNOSTIC, AND CANCER THERAPEUTIC USES OF FANCI AND FANCI MODULATING AGENTS | MILTENYI BIOTEC GMBH (DE) | 2013-10-24 | — | — | US | disclosed |
| US-8541198-B2 | Method for determination and quantification of radiation or genotoxin exposure | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-8541192-B2 | Methods to identify USP1 deubiquitinating enzyme complex inhibitors | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2013-09-24 | — | — | US | disclosed |
| US-20110312514-A1 | Method For Determination And Quantification Of Radiation Or Genotoxin Exposure | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-12-22 | — | — | US | disclosed |
| US-20110269817-A1 | COMPOSITIONS AND METHODS RELATED TO SIRT1 FUNCTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110151487-A1 | Compositions And Methods For The Treatment Of Cancer | DANA-FARBER CANCER INSTITUTE, INC. | 2011-06-23 | — | — | US | disclosed |
| EP-2315600-A2 | COMPOSITIONS AND METHODS RELATED TO SIRT1 FUNCTION | The Regents of the University of California (US) | 2011-05-04 | — | — | EP | disclosed |
| US-7910325-B2 | Screening agents which modulate formation of Fanconi anemia complementation group D2 (FANC D2) -containing foci; cell expressing polynucleotide comprising DNA sequence encoding protein; determining a subject's sensitivity to a genotoxic agent | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2011-03-22 | — | — | US | disclosed |
| EP-0485591-A4 | METHOD OF ISOLATING RESTRICTION FRAGMENT DELETIONS IN -I(VIBRIO CHOLERAE), AND PRODUCTS THEREOF | — | 1993-07-14 | — | — | EP | disclosed |
| EP-0517413-A1 | Fermentation of a triol heptanoic acid by mutant strains of aspergillus terreus | MERCK & CO. INC. (US) | 1992-12-09 | — | — | EP | disclosed |
| US-5135862-A | METHOD OF ISOLATING RESTRICTION FRAGMENT DELETIONS IN VIBRIO CHOLERAE, PRODUCTS THEREOF | UNIVERSITY OF MARYLAND (US) | 1992-08-04 | — | — | US | disclosed |
| EP-0485591-A1 | METHOD OF ISOLATING RESTRICTION FRAGMENT DELETIONS IN -i(VIBRIO CHOLERAE), AND PRODUCTS THEREOF. | UNIV MARYLAND (US) | 1992-05-20 | — | — | EP | disclosed |
| WO-1991018979-A1 | METHOD OF ISOLATING RESTRICTION FRAGMENT DELETIONS IN VIBRIO CHOLERAE, AND PRODUCTS THEREOF | UNIVERSITY OF MARYLAND AT BALTIMORE (US) | 1991-12-12 | — | — | WO | disclosed |
| EP-0179864-B1 | PROCESS FOR PREPARING L-CARNITINE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1990-08-22 | — | — | EP | disclosed |
| US-4751182-A | AEROBIC DEGRADATION OF RACEMIC MIXTURE USING NEISSERIA MICROORGANISMS | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1988-06-14 | — | — | US | disclosed |
| EP-0179864-A4 | PROCESS FOR PREPARING L-CARNITINE. | WISCONSIN ALUMNI RES FOUND (US) | 1987-01-20 | — | — | EP | disclosed |
| EP-0179864-A1 | PROCESS FOR PREPARING L-CARNITINE. | WISCONSIN ALUMNI RES FOUND (US) | 1986-05-07 | — | — | EP | disclosed |
| WO-1985004900-A1 | PROCESS FOR PREPARING L-CARNITINE | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 1985-11-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269817-A1 | COMPOSITIONS AND METHODS RELATED TO SIRT1 FUNCTION | CRY1, PER2, SIRT1 | PNP 3131/4885DPP4 2167/4885PDPK1 1224/4885 |
| US-20130280258-A1 | PROGNOSTIC, DIAGNOSTIC, AND CANCER THERAPEUTIC USES OF FANCI AND FANCI MODULATING AGENTS | FANCI, FANCF, FANCD2 | PNP 2237/4885DPP4 4709/4885PDPK1 986/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.